Patent Document ID: 9474772
Application ID: 14693245
Patent Flag: 1

Claim One:
1. A method for generating a composition comprising non-pluripotent progenitors of surrogate pancreatic cells that are suitable for treating insulin-dependent diabetes, comprising: a. harvesting human cells from viable human pancreatic tissue in minimal, defined culture conditions; b. culturing the primary human cells for a period of days that is fewer than about 9 days; then c. delivering reprogramming genes into the primary human cells from (b) to reprogram the primary human cells to obtain reprogrammed cells such that no reprogramming genes are integrated into the genome of the reprogrammed cells, wherein the reprogrammed cells have a stem cell morphology; d. firstly selecting among the reprogrammed cells obtained in (c) for an ability to proliferate, without losing said stem cell morphology, in minimal, defined culture conditions whereby proliferating reprogrammed cells are obtained; and then e. secondly selecting from among the proliferating reprogrammed cells for a cell population characterized by (i) an ability to survive and differentiate to a pancreatic lineage in the course of a protocol that employs only defined reagents, and (ii) a substantial inability to differentiate to a mesodermal lineage, whereby said non-pluripotent progenitors are obtained.